Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 avr. 2026 09h15 HE | Source: Myriad Genetics, Inc.

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of...
27 janv. 2026 08h50 HE | Source: Myriad Genetics, Inc.

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection.
25 nov. 2025 16h15 HE | Source: Myriad Genetics, Inc.

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

Clairity, Myriad Genetics, and MagView announce a joint collaboration in an effort to identify more women at high risk for breast cancer.